Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-AKY-2519 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on 225Ac-AKY-2519, a putative radioconjugate targeting CD276 (B7-H3) (May 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-AKY-2519 | [225]Ac-AKY-2519|225Ac]Ac-AKY-2519 | CD276 Antibody 25 | Limited information is currently available on 225Ac-AKY-2519, a putative radioconjugate targeting CD276 (B7-H3) (May 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07581184 | Phase I | 225Ac-AKY-2519 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer (BActinium-1) | Recruiting | USA | 0 |